Market Cap 330.51B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 18.00
Forward PE 15.43
Profit Margin 7.59%
Debt to Equity Ratio 47.80
Volume 4,344,400
Avg Vol 6,356,692
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 63%
Beta 0.48
Analysts Strong Sell
Price Target $209.84

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
maq34
maq34 Jul. 24 at 12:15 PM
Source: AtriCure, Inc. $ATRC on the move $MRNA $JNJ $ABBV https://share.google/IpxwMxrvlssU9S3yq
0 · Reply
mydogabbymoon
mydogabbymoon Jul. 24 at 11:00 AM
$ABBV "earnings" call 1 week from today....how badly are we going to tank?
0 · Reply
Trader_Ty
Trader_Ty Jul. 24 at 1:52 AM
$ABBV Sitting over that big base for a while now
0 · Reply
Quantumup
Quantumup Jul. 23 at 6:25 PM
H.C. Wainwright reit'd $ORKA Buy/$45 after Oruka📰that the FDA had cleared its IND application for its Phase 2a trial of ORKA-001 (the company's long-acting anti-IL-23p19 antibody) in moderate-to-severe PsO, called EVERLAST-A. $ABBV $PTGX - $JNJ #EDAV25 H.C. Wainwright said in its note: "This program is a randomized, double-blind, placebo-controlled Phase 2a trial designed to evaluate the safety and efficacy of a single dose level of ORKA-001 in moderate-to-severe psoriasis patients. EVERLAST-A will enroll approximately 80 patients, randomized 3:1 to receive ORKA-001 or matching placebo. The primary endpoint is PASI 100 at Week 16. ORKA-001 exposures are expected to match or exceed exposures in the KNOCKOUT study, providing a definitive test of whether higher exposures of an anti-IL-23p19 antibody can lead to greater efficacy. H.C. Wainwright went on to say:
0 · Reply
Buzzdaq
Buzzdaq Jul. 23 at 5:26 PM
$ABBV roll Jul25 192.5c >> Aug8 195c
0 · Reply
RunnerSignals
RunnerSignals Jul. 23 at 4:57 PM
Pullback party? $AMAT $HPE $ABBV $GS $DAL are dusting off the dip and looking for the next leg up
0 · Reply
Quantumup
Quantumup Jul. 23 at 12:07 PM
Citizens⬆️ $ABVX to $95, reit Mkt-OP &said, "Stellar Phase 3 results for obefazimod in ulcerative colitis support potential for broad and early use in clinical practice" $ABBV $BMY PFE TAK $JNJ $PTGX VYTX LLY Guggenheim⬆️ $ABVX $101, reit Buy &said data clearly beat its/Buyside's exps.—believes obe S/B valued $7-10B range, given the recent M&A comps—Gugg's KOL called data "striking" Citizens said, "we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target to $95 from $33 on Abivax SA. Yesterday afternoon, Abivax announced positive results from the two Phase 3 induction trials for obefazimod in moderate-to-severe ulcerative colitis. We view the results as highly compelling, with a pooled, placebo-adjusted clinical remission rate of 16.4% (p<0.0001) and a clean safety/tolerability profile. We raise our probability of approval and sales projections for the candidate, driving our increased price target." Guggenheim in its note said:
0 · Reply
StockAutoPro
StockAutoPro Jul. 22 at 9:52 PM
$ABBV: at $187.11 Buy target $185.11 Sell target $196.47 Strong pipeline replacing Humira exclusivity loss
0 · Reply
Heare2dare
Heare2dare Jul. 22 at 7:53 PM
0 · Reply
SonGoku
SonGoku Jul. 22 at 5:59 PM
Health care sector cheap $XLV $ABBV $JNJ $UNH LLY
0 · Reply
Latest News on ABBV
Final Trades: Abbvie, Uber, Western Union and Live Nation

Jul 23, 2025, 1:25 PM EDT - 19 hours ago

Final Trades: Abbvie, Uber, Western Union and Live Nation

LYV UBER WU


4 Reasons To Buy AbbVie

Jul 22, 2025, 11:21 AM EDT - 1 day ago

4 Reasons To Buy AbbVie


Best Dividend Kings: July 2025

Jul 22, 2025, 9:31 AM EDT - 1 day ago

Best Dividend Kings: July 2025

ABM ABT ADM ADP AWR BDX BKH


Why AbbVie Is a Strong Buy for Long-Term Investors in 2025

Jul 18, 2025, 5:13 AM EDT - 6 days ago

Why AbbVie Is a Strong Buy for Long-Term Investors in 2025


My Top 2 Earnings Picks For This Earnings Season

Jul 16, 2025, 4:05 PM EDT - 7 days ago

My Top 2 Earnings Picks For This Earnings Season

PAAS


Why Is AbbVie Stock Trading Higher On Thursday?

Jul 10, 2025, 2:36 PM EDT - 13 days ago

Why Is AbbVie Stock Trading Higher On Thursday?


Final Trades: Abbvie, Boeing, Oracle and Joby Aviation

Jul 10, 2025, 2:03 PM EDT - 13 days ago

Final Trades: Abbvie, Boeing, Oracle and Joby Aviation

BA JOBY ORCL


2 ETFs To Prepare You For A Potential Recession

Jul 7, 2025, 6:50 AM EDT - 17 days ago

2 ETFs To Prepare You For A Potential Recession

AVGO


AbbVie to buy Capstan Therapeutics for up to $2.1 billion

Jun 30, 2025, 8:42 AM EDT - 23 days ago

AbbVie to buy Capstan Therapeutics for up to $2.1 billion


AbbVie to Host Second-Quarter 2025 Earnings Conference Call

Jun 30, 2025, 8:00 AM EDT - 24 days ago

AbbVie to Host Second-Quarter 2025 Earnings Conference Call


Best Dividend Aristocrats For July 2025

Jun 29, 2025, 7:19 AM EDT - 25 days ago

Best Dividend Aristocrats For July 2025

ABT ADM ADP AFL ALB AMCR AOS


2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'

Jun 24, 2025, 8:00 AM EDT - 4 weeks ago

2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'

BKH


I'm Buying Dividend Giants At Huge Discounts

Jun 20, 2025, 9:00 AM EDT - 4 weeks ago

I'm Buying Dividend Giants At Huge Discounts

BMY CVX OXY PFE SHEL SLB TTE


AbbVie Declares Quarterly Dividend

Jun 20, 2025, 8:00 AM EDT - 4 weeks ago

AbbVie Declares Quarterly Dividend


AbbVie's migraine drug meets main goal of late-stage study

Jun 18, 2025, 7:27 AM EDT - 5 weeks ago

AbbVie's migraine drug meets main goal of late-stage study


AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow

Jun 17, 2025, 6:42 AM EDT - 5 weeks ago

AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow


AbbVie says blood cancer drug fails late-stage trial

Jun 16, 2025, 9:12 AM EDT - 5 weeks ago

AbbVie says blood cancer drug fails late-stage trial


AbbVie: Margin Clarity, Dividend Durability Awaited

Jun 16, 2025, 5:05 AM EDT - 5 weeks ago

AbbVie: Margin Clarity, Dividend Durability Awaited


AbbVie Moves From Blockbuster Loss To Market Domination

Jun 16, 2025, 1:29 AM EDT - 5 weeks ago

AbbVie Moves From Blockbuster Loss To Market Domination


AbbVie's Post-Humira Strategy Is Paying Off For Investors

Jun 15, 2025, 7:11 AM EDT - 5 weeks ago

AbbVie's Post-Humira Strategy Is Paying Off For Investors


Bert's May 2025 Dividend Income Summary

Jun 3, 2025, 1:43 PM EDT - 7 weeks ago

Bert's May 2025 Dividend Income Summary

C CZNC KMI NSC O PG SBUX


maq34
maq34 Jul. 24 at 12:15 PM
Source: AtriCure, Inc. $ATRC on the move $MRNA $JNJ $ABBV https://share.google/IpxwMxrvlssU9S3yq
0 · Reply
mydogabbymoon
mydogabbymoon Jul. 24 at 11:00 AM
$ABBV "earnings" call 1 week from today....how badly are we going to tank?
0 · Reply
Trader_Ty
Trader_Ty Jul. 24 at 1:52 AM
$ABBV Sitting over that big base for a while now
0 · Reply
Quantumup
Quantumup Jul. 23 at 6:25 PM
H.C. Wainwright reit'd $ORKA Buy/$45 after Oruka📰that the FDA had cleared its IND application for its Phase 2a trial of ORKA-001 (the company's long-acting anti-IL-23p19 antibody) in moderate-to-severe PsO, called EVERLAST-A. $ABBV $PTGX - $JNJ #EDAV25 H.C. Wainwright said in its note: "This program is a randomized, double-blind, placebo-controlled Phase 2a trial designed to evaluate the safety and efficacy of a single dose level of ORKA-001 in moderate-to-severe psoriasis patients. EVERLAST-A will enroll approximately 80 patients, randomized 3:1 to receive ORKA-001 or matching placebo. The primary endpoint is PASI 100 at Week 16. ORKA-001 exposures are expected to match or exceed exposures in the KNOCKOUT study, providing a definitive test of whether higher exposures of an anti-IL-23p19 antibody can lead to greater efficacy. H.C. Wainwright went on to say:
0 · Reply
Buzzdaq
Buzzdaq Jul. 23 at 5:26 PM
$ABBV roll Jul25 192.5c >> Aug8 195c
0 · Reply
RunnerSignals
RunnerSignals Jul. 23 at 4:57 PM
Pullback party? $AMAT $HPE $ABBV $GS $DAL are dusting off the dip and looking for the next leg up
0 · Reply
Quantumup
Quantumup Jul. 23 at 12:07 PM
Citizens⬆️ $ABVX to $95, reit Mkt-OP &said, "Stellar Phase 3 results for obefazimod in ulcerative colitis support potential for broad and early use in clinical practice" $ABBV $BMY PFE TAK $JNJ $PTGX VYTX LLY Guggenheim⬆️ $ABVX $101, reit Buy &said data clearly beat its/Buyside's exps.—believes obe S/B valued $7-10B range, given the recent M&A comps—Gugg's KOL called data "striking" Citizens said, "we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target to $95 from $33 on Abivax SA. Yesterday afternoon, Abivax announced positive results from the two Phase 3 induction trials for obefazimod in moderate-to-severe ulcerative colitis. We view the results as highly compelling, with a pooled, placebo-adjusted clinical remission rate of 16.4% (p<0.0001) and a clean safety/tolerability profile. We raise our probability of approval and sales projections for the candidate, driving our increased price target." Guggenheim in its note said:
0 · Reply
StockAutoPro
StockAutoPro Jul. 22 at 9:52 PM
$ABBV: at $187.11 Buy target $185.11 Sell target $196.47 Strong pipeline replacing Humira exclusivity loss
0 · Reply
Heare2dare
Heare2dare Jul. 22 at 7:53 PM
0 · Reply
SonGoku
SonGoku Jul. 22 at 5:59 PM
Health care sector cheap $XLV $ABBV $JNJ $UNH LLY
0 · Reply
ZacksResearch
ZacksResearch Jul. 22 at 5:38 PM
$ABBV: Neuroscience Growth, But Is It Enough? 🤔 AbbVie’s neuroscience sales are projected to hit $2.5B in Q2 2025, a 15% YoY jump, led by Botox and Vraylar. Yet, investor focus remains on its immunology giants as results loom July 31. Full analysis here 👉 https://www.zacks.com/stock/news/2603129/how-will-abbvies-neuroscience-franchise-perform-in-q2-earnings?cid=sm-stocktwits-2-2603129-body-2987&ADID=SYND_STOCKTWITS_TWEET_2_2603129_BODY_2987
0 · Reply
ZacksResearch
ZacksResearch Jul. 22 at 2:06 PM
$ABBV's neuroscience biz set to pop 15% — can it aid Q2 earnings? Growth powered by Botox Therapeutic, Vraylar, and oral migraine drug sales is expected to drive the upside. Full earnings setup here 👉 https://www.zacks.com/stock/news/2603129/how-will-abbvies-neuroscience-franchise-perform-in-q2-earnings?cid=sm-stocktwits-2-2603129-teaser-2986&ADID=SYND_STOCKTWITS_TWEET_2_2603129_TEASER_2986
0 · Reply
V9RDPUMA
V9RDPUMA Jul. 22 at 1:12 AM
$ABBV WTF is wrong with this pos that I have owned since the spin out from ABT??? Up 10 points one week, down 10 the next??!!! Frustrating pos.
0 · Reply
mydogabbymoon
mydogabbymoon Jul. 21 at 8:27 PM
$ABBV this POS....
0 · Reply
PanicSeller8
PanicSeller8 Jul. 21 at 7:48 PM
$ABBV I'm surprised how poorly this has performed of late on seemingly no news other than vague pharma tariff talk.
0 · Reply
Godwins26
Godwins26 Jul. 21 at 5:50 PM
$ABBV and $IXHL Let's Go!!!!
0 · Reply
scottybebs
scottybebs Jul. 21 at 3:59 PM
$ABBV don’t like this before earnings
0 · Reply
SonGoku
SonGoku Jul. 21 at 1:38 PM
0 · Reply
Quantumup
Quantumup Jul. 21 at 1:15 PM
Stifel reiterated $ORKA Buy-$47 after $ORKA's disclosure of the IND clearance for ORKA-001 and then catching up w/ mgmt.. $ABBV $PTGX $JNJ #EADV25 UCBJY $MLTX Stifel said in its note: "We caught up with management who noted that the IND clearance was based on interim Ph1 data (safety/tolerability) and Ph2a sites are open and actively enrolling -- Ph1 results to be presented at #EADV in September. Recall, ORKA-001 is a next-gen IL-23p19 which is designed to explore greater exposure and improved dosing vs. mega-blockbuster Skyrizi based on exploratory IST results in Psoriasis demonstrating superior efficacy/potential for remission in patients dosed with 4x the normal psoriasis dose (LINK). Meanwhile, $ORKA is on track to release Ph1 data for ORKA-002 (next-gen IL-17A/F mAb) by YE25 following a continued strong launch for Bimzelx and upcoming Ph3 data for $MLTX's sonelokimab -- there is currently limited investor focus on $ORKA as a player in the IL-17A/F space."
0 · Reply
StockAutoPro
StockAutoPro Jul. 21 at 3:01 AM
$ABBV: trading $155 Buy target $175 Sell target $200 Humira loss offset pipeline growth remains
0 · Reply
FATSTAX
FATSTAX Jul. 19 at 4:06 PM
$SPY $QQQ $ABBV Weekly 10 ema = silver line Pros = white candles Build over the $188.70 4/25 high is a 10 ema breakout & $198.98 5/2 high retest threat.
0 · Reply
wealth35_
wealth35_ Jul. 19 at 8:44 AM
$ABBV https://www.zacks.com/stock/news/2591438/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know?cid=CS-STOCKTWITS-HL-tale_of_the_tape%7Cmost_searched_stocks-2591438&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_566_2591438
0 · Reply